The American Society of Hematology (ASH) Annual Meeting & Exposition began December 5 with numerous presentations, abstracts and posters.
MacroGenics Inc. announced a partnership with Eversana to commercialize margetuximab in the United States, if approved.
Urovant’s Irritable Bowel Drug Fails in Phase II; Genmab Abandons Cancer Drug
Abdominal Pain, Antibody-Drug Conjugates (ADCs), Biomarkers, Business, Cancer, Clinical Trials, Irritable Bowel Syndrome with Diarrhea (IBS-D), Monoclonal Antibodies, Product Pipelines, R&D, Shares, Small Molecules, Solid Tumors, Topline DataUrovant Sciences and Genmab reported disappointing clinical trial announcements.
The U.S. government will start distributing Regeneron Pharmaceuticals Inc.’s newly authorized Covid-19 antibody combination on Nov. 24, beginning with more than 30,000 treatment courses, a health official said.
The U.S. Food and Drug Administration issued emergency use authorization for Regeneron Pharmaceuticals Inc.’s Covid-19 antibody therapy, an experimental treatment given to U.S. President Donald Trump that he said helped cure him of the disease.
AstraZeneca started late-stage trials of an experimental long-acting monoclonal antibody combination drug the company hopes could be used as a so-called prophylactic to prevent Covid-19 infection in at-risk people for up to 12 months.
The U.S. Food and Drug Administration issued a Complete Response Letter (CRL) for Sanofi’s blood cancer treatment sutimlimab.
How Effective Will Lilly’s Bamlanivimab be in the Battle Against Covid-19?
Adults 65 and Older, Analysis, Bamlanivimab (LY-CoV555), Clinical Data, Clinical Trials, Coronavirus Disease 2019 (COVID-19), Emergency Use Authorization, FDA, Hospitalized COVID-19 Patients, Humanized IgG1 monoclonal antibody, Monoclonal Antibodies, R&D, ReutersThere are some questions about how effective Eli Lilly’s antibody neutralizing antibody bamlanivimab (LY-CoV555) will prove to be in the battle against Covid-19 due to labeling limitations.
U.S. allows emergency use of first Covid-19 antibody drug
Adults 65 and Older, Business, Clinical Trials, COVID-19 antibody drugs, Dr. Anthony Fauci (Director), Emergency Use Authorization, FDA, Hospitalized COVID-19 Patients, Monoclonal Antibodies, R&D, Regeneron Pharmaceuticals, Shares, White HouseU.S. regulators authorized emergency use of the first experimental antibody drug for Covid-19 in patients who are not hospitalized but are at risk of serious illness because of their age or other conditions.
A World Health Organization-led scheme to supply Covid-19 drugs to poor countries is betting on experimental monoclonal antibody treatments and steroids but shunning Gilead’s remdesivir therapy, an internal document shows.